Fig. 2

BAY 2402234 induces differentiation and inhibits proliferation of leukemia cells in vitro. a, b MOLM-13 (a) and HEL (b) cells were treated with increasing concentrations of BAY 2402234 for 4 days in the presence (blue) or absence (green) of 100 µM uridine and CD11b fluorescence intensity was then measured by FACS (RFU = relative fluorescence units). c TF-1 cells were treated for 3 or 6 days with the indicated concentrations of BAY 2402234 in the presence or absence of uridine and the percent CD11b-positive cells was determine by FACS. d THP-1 cells were treated with increasing concentrations of BAY 2402234 in the presence or absence of 100 µM uridine for 3 days and the number of surviving cells was then determined by Cell Titer Glow Assay (RLU = relative luminescence units). e–g TF-1 cells were treated with the indicated concentrations of BAY 2402234 in the presence or absence of uridine for a total of 9 days. The number of viable cells on days 3, 6 and 9 (e), the cell cycle state of the cells on day 3 (f) and the percent apoptotic cells on days 3 and 6 (g) were assessed. By day 9, no viable BAY 2402234-treated cells were detectable. Graphs f and g are representative results from three biological replicates